Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

Isani, Sara

314 - Poster Session A
Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

Saturday, March 22, 2014: 8:25 PM

West Exhibit Hall (Tampa Convention Center)

S. S. Isani¹, A. G. Rodriguez-Gabin², G. L. Goldberg³, S. B. Horwitz² and H. M. McDaid²
¹Rutgers Cancer Institute of New Jersey/ Robert Wood Johnson Medical School, New Brunswick, NJ, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

314 - Poster Session A
Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

314 - Poster Session A Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

314 - Poster Session A
Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer